title: Clinical aspects of Helicobacter pylori infection.
abstract: The Helicobacter pylori (Hp) infection is common. However, only 10-20% of infected individuals require antibacterial treatment. The main indications to such treatment are peptic ulcer disease, atrophic gastritis, dyspeptic symptoms, previous surgical procedure for gastric cancer, family history of gastric cancer and low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma. The treatment may also be undertaken at the patient's request. To detect the infection the urease test (when the patient has indications for gastroscopy), the urea breath test or serologic test are most commonly used. A standard treatment of Hp infection consists of a 7-day administration of one of the proton pump inhibitors and 2 out of 3 antibiotics such as amoxicillin, clarithromycin and metronidazole. After failure of the first-line treatment, the recommended second choice treatment is a quadruple treatment regimen consisting of bismuth salts, tetracycline, metronidazole and proton pump inhibitor. European guidelines (Maastricht III) allow the use of the quadruple treatment regimen already as the first choice treatment and therapy prolongation up to 14 days. Ineffectiveness of the second-line treatment is an indication for antimicrobial susceptibility testing. New antibiotics used for Hp eradication are levofloxacin and rifabutin. Eradication treatment should be obligatorily assessed with the use of the urease or breath test only in patients with peptic ulcer bleeding. The current guidelines do not envisage an active search for Hp infection in an asymptomatic population and treating people infected with this bacterium, for gastric cancer prevention.
authors: Department of Gastroenterology and Hepatology CMKP, Center of Oncology, Warsaw, Poland. wbartnik@coi.waw.pl
authors: Witold
authors: W
authors: Bartnik
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D017410:Practice Guidelines as Topic; D013272:Stomach Diseases / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents